Companies / Hansa Biopharma
Hansa Biopharma
Sweden
Hansa Biopharma develops innovative immunomodulating therapies for people affected by rare immunologic conditions.
Its site was last checked 14 Nov 2026: site answers.
Investors
none on file yetNo investor VCinfo tracks lists Hansa Biopharma yet.
In the news
2 headlines naming Hansa BiopharmaEach headline is matched with evidence and opens on its outlet. Some come through the GDELT Project.
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Hansa Biopharma and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when an investor you follow adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/hansabiopharma.com/investors
# also
GET /v1/companies/hansabiopharma.com
GET /v1/companies/hansabiopharma.com/news